The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients (Q34240314)

31 July 2017

title

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients (English)

1 reference

31 July 2017

Ulrike Bacher

1 reference

31 July 2017

Francis Ayuk

1 reference

31 July 2017

Evgeny Klyuchnikov

1 reference

31 July 2017

Nicolaus Kröger

1 reference

31 July 2017

Ilya Kazantsev

1 reference

31 July 2017

Tatjana Zabelina

1 reference

31 July 2017

Axel Rolf Zander

1 reference

31 July 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20981158

11 August 2024

publication date

26 October 2010

1 reference

full work available at URL

31 July 2017

http://downloads.hindawi.com/journals/ah/2011/974658.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20981158

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20981158/?tool=EBI

11 August 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20981158

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20981158/pdf/?tool=EBI

11 August 2024

file format

Portable Document Format

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20981158

https://europepmc.org/articles/PMC2964008

11 August 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20981158

https://europepmc.org/articles/PMC2964008?pdf=render

11 August 2024

file format

Portable Document Format

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20981158

11 August 2024

published in

Advances in Hematology

1 reference

31 July 2017

volume

2011

1 reference

31 July 2017

page(s)

974658

1 reference

Creative Commons Attribution 3.0 Unported

31 July 2017

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

The biology of Hodgkin's lymphoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

State-of-the-art therapeutics: Hodgkin's lymphoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic diffuse lung injury syndromes

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group

28 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

The role of cytokines in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Tumor-associated macrophages and survival in classic Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Refractory Hodgkin lymphoma responds to pentostatin (2'-deoxycoformycin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Experience with 90Y-ibritumomab tiuxetan for relapsed classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin’s lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Second autologous stem cell transplant for multiply relapsed Hodgkin's disease

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964008

RNA fingerprints provide direct evidence for the inhibitory role of TGF and PD-1 on CD4+ T cells in Hodgkin lymphoma

28 October 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F974658

Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim

21 January 2018

1 reference

12 December 2020

Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC

1 reference

12 December 2020

Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma

1 reference

12 December 2020

Immune escape mechanisms in Hodgkin's disease

1 reference

12 December 2020

Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients

1 reference

12 December 2020

Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation

1 reference

12 December 2020

Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma

1 reference

12 December 2020

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia

1 reference

12 December 2020

Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation

1 reference

12 December 2020

Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody

1 reference

12 December 2020

Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma

1 reference

12 December 2020

Graft-versus-myeloma effect: proof of principle

1 reference

12 December 2020

Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy

1 reference

12 December 2020

High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices

1 reference

12 December 2020

Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma

1 reference

12 December 2020

Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival

1 reference

12 December 2020

Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen

1 reference

12 December 2020

Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation

1 reference

12 December 2020

Allogeneic marrow transplantation for refractory Hodgkin's disease

1 reference

12 December 2020

High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver

1 reference

12 December 2020

Long-term results of blood and marrow transplantation for Hodgkin's lymphoma

1 reference

12 December 2020

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience

1 reference

12 December 2020

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

12 December 2020

Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases

1 reference

12 December 2020

Identifiers

DOI

10.1155/2011/974658

1 reference

31 July 2017

1 reference

31 July 2017

1 reference